Company / R&D Expense
KESTRA MEDICAL TECHNOLOGIES, LTD. R&D Expense History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$15.7M
FY2024
5-year range
$15.5M / $15.7M
FY2023-FY2024
Trend
+1.0%
vs FY2023
Sector context
#100 of 110
Health Care
What the data says
Among 110 Health Care companies, KESTRA MEDICAL TECHNOLOGIES, LTD. is in the bottom 9% for r&d expense.
Based on SEC 10-K filings.
$16M in FY2024.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 110This company $15.7M Sector average $298.2M
▼
-94.8% below sector average
Key checks
Key Insights
- In FY2024, r&d expense increased 1.0% year-over-year.
- Ranks #100 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $15.7M | +1.0% |
| FY2023 | $15.5M | - |
As of FY2024 · SEC 10-K · Updated Mar 29, 2026